全文获取类型
收费全文 | 1032篇 |
免费 | 53篇 |
国内免费 | 42篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 31篇 |
妇产科学 | 8篇 |
基础医学 | 155篇 |
口腔科学 | 17篇 |
临床医学 | 140篇 |
内科学 | 220篇 |
皮肤病学 | 28篇 |
神经病学 | 30篇 |
特种医学 | 213篇 |
外科学 | 73篇 |
综合类 | 17篇 |
预防医学 | 70篇 |
眼科学 | 16篇 |
药学 | 41篇 |
中国医学 | 1篇 |
肿瘤学 | 60篇 |
出版年
2021年 | 5篇 |
2019年 | 8篇 |
2018年 | 15篇 |
2017年 | 8篇 |
2016年 | 6篇 |
2015年 | 26篇 |
2014年 | 21篇 |
2013年 | 35篇 |
2012年 | 29篇 |
2011年 | 29篇 |
2010年 | 39篇 |
2009年 | 27篇 |
2008年 | 35篇 |
2007年 | 50篇 |
2006年 | 32篇 |
2005年 | 33篇 |
2004年 | 23篇 |
2003年 | 13篇 |
2002年 | 17篇 |
2001年 | 13篇 |
2000年 | 15篇 |
1999年 | 18篇 |
1998年 | 37篇 |
1997年 | 38篇 |
1996年 | 41篇 |
1995年 | 37篇 |
1994年 | 48篇 |
1993年 | 26篇 |
1992年 | 18篇 |
1991年 | 18篇 |
1990年 | 19篇 |
1989年 | 41篇 |
1988年 | 44篇 |
1987年 | 42篇 |
1986年 | 32篇 |
1985年 | 25篇 |
1984年 | 23篇 |
1983年 | 14篇 |
1982年 | 11篇 |
1981年 | 10篇 |
1980年 | 12篇 |
1978年 | 5篇 |
1977年 | 10篇 |
1976年 | 8篇 |
1975年 | 8篇 |
1969年 | 5篇 |
1967年 | 5篇 |
1966年 | 5篇 |
1930年 | 4篇 |
1929年 | 5篇 |
排序方式: 共有1127条查询结果,搜索用时 250 毫秒
101.
We hypothesised that initiating heavy-intensity exercise from an elevated baseline metabolic rate would result in slower Phase II O2 uptake V(O2) kinetics and a greater overall 'gain' in V(O2) per unit increase in work rate. Seven healthy males performed a series of like-transitions on a cycle ergometer: (1) from light exercise to 'moderate' exercise (80% of the gas exchange threshold, GET; L-->M); (2) from light exercise to 'heavy' exercise (40% of the difference between GET and V(O2) peak; L-->H); (3) from moderate exercise to heavy exercise (M-->H). The Phase II time constant (tau) was significantly (P<0.01) greater in the M-->H condition (48+/-11 s) compared to the L-->M and L-->H conditions (26+/-6 s versus 27+/-4 s, respectively). Moreover, the end-exercise 'gain' values were significantly different between the three conditions (L-->M, 8.1+/-0.7 mL min-1 W-1; L-->H, 9.7+/-0.4 mL min-1 W-1; M-->H, 10.7+/-0.7 mL min-1 W-1; P<0.05). This 'non-linearity' in the pulmonary V(O2) response to exercise might be attributed, at least in part, to differences in the metabolic properties of the muscle fibres recruited in the abrupt transition from a lower to a higher work rate. 相似文献
102.
自体骨粉移植修复下颌骨部分缺损的组织学检测 总被引:2,自引:2,他引:2
目的:通过动物实验进行组织学光镜及扫描电镜检测,观察自体骨粉移植修复下颌骨缺损的愈合过程。方法:实验于2005-05/11在南方医科大学动物实验中心完成,选用12只健康雄性大耳白兔。实验分为两组:一侧为自体骨粉移植组,另一侧为空白对照组,均采用自体左右对照。①缺损模型建立:于双侧下颌骨体部下缘用磨削机器各造成1.0×1.0cm的全层骨缺损。②自体骨粉移植:将所有自体骨粉回填一侧缺损处作为自体骨粉移植组,另一侧缺损旷置作为空白对照组。③分别于术后2,4及8周各处死4只动物,获取整块下颌骨标本作组织学光镜及扫描电镜检测,光镜切片应用苏木精-伊红染色,扫描电镜只观察自体骨粉移植组标本。结果:12只大耳白兔均进入结果分析,无脱失。①两组标本组织学观察结果:自体骨粉移植组术后2周时形成薄层骨痂;4周时为新生的骨小梁,但排列紊乱;8周时骨小梁形成的编织骨已逐渐向板层骨过渡。空白对照组术后8周时骨小梁分布仍稀疏。②自体骨粉移植组标本超微结构观察结果:术后4周骨基质钙化程度提高,大量成骨细胞位于骨陷窝内。缺损间隙逐渐变窄形成多孔较疏松的新骨组织,新生骨小梁形成,新骨超微结构呈“蜂窝状”。8周时骨小梁钙化程度继续升高,形成的板状骨排列出现一定方向性,新生骨组织由多孔疏松的结构向致密性结构转化,新原骨组织基本上融为一体产生骨性结合,髓腔相通。结论:自体骨粉移植修复下颌骨成骨可靠,愈合加快,愈合方式以骨传导爬行替代为主,且应用方法简便。 相似文献
103.
Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood 总被引:7,自引:4,他引:7
Wada M; Bartram CR; Nakamura H; Hachiya M; Chen DL; Borenstein J; Miller CW; Ludwig L; Hansen-Hagge TE; Ludwig WD 《Blood》1993,82(10):3163-3169
p53 mutations are found in a wide variety of cancers, including hematologic malignancies. These alterations apparently contribute to development of the malignant phenotype. We analyzed a large series of lymphoid (330 cases) and a smaller series of myeloid (29 cases) malignancies of childhood for p53 mutations by single-strand conformational polymorphism (SSCP) following polymerase chain reaction. Samples with abnormal SSCP were reamplified and analyzed by direct sequencing method. p53 mutations were detected within the known mutational hotspots (exons 5 to 8) in 8 of 330 lymphoid malignancies, and in none of 29 myeloid malignancies, showing that the frequency of p53 mutations in childhood lymphoid malignancies was very low (8 of 330 cases [2%]). Four of these patients had very aggressive, fatal acute lymphocytic leukemia (ALL). None of 13 infants and none of 48 patients with T-lineage leukemia had detectable p53 mutations in their ALL cells. Exceptionally, p53 mutations were comparatively frequent in a small sample of B-cell non-Hodgkin's lymphomas (2 of 8 cases). Mutations were detected in samples from two patients with ALL at relapse; these were not detected in samples at initial diagnosis from the same patients, suggesting that p53 mutations may be associated with progression to a more malignant phenotype. Seven of eight alterations of p53 were missense mutations, and seven of eight samples may be heterozygous for the mutant p53, indicating that p53 protein may act in a dominant negative fashion. 相似文献
104.
Marianne S. Poruchynsky Edina Komlodi-Pasztor Shana Trostel Julia Wilkerson Marie Regairaz Yves Pommier Xu Zhang Tapan Kumar Maity Robert Robey Mauricio Burotto Dan Sackett Udayan Guha Antonio Tito Fojo 《Proceedings of the National Academy of Sciences of the United States of America》2015,112(5):1571-1576
The paradigm that microtubule-targeting agents (MTAs) cause cell death via mitotic arrest applies to rapidly dividing cells but cannot explain MTA activity in slowly growing human cancers. Many preferred cancer regimens combine a MTA with a DNA-damaging agent (DDA). We hypothesized that MTAs synergize with DDAs by interfering with trafficking of DNA repair proteins on interphase microtubules. We investigated nine proteins involved in DNA repair: ATM, ATR, DNA-PK, Rad50, Mre11, p95/NBS1, p53, 53BP1, and p63. The proteins were sequestered in the cytoplasm by vincristine and paclitaxel but not by an aurora kinase inhibitor, colocalized with tubulin by confocal microscopy and coimmunoprecipitated with the microtubule motor dynein. Furthermore, adding MTAs to radiation, doxorubicin, or etoposide led to more sustained γ-H2AX levels. We conclude DNA damage-repair proteins traffic on microtubules and addition of MTAs sequesters them in the cytoplasm, explaining why MTA/DDA combinations are common anticancer regimens.First developed as anticancer agents in the 1950s, microtubule targeting agents (MTAs) are used in the treatment of a wide variety of malignancies and until now have been thought to kill cells by arresting them in mitosis (1, 2). Although this explanation applies to rapidly dividing cells in preclinical models, it cannot explain the activity of these agents in tumors in humans because these cells divide much more slowly. For the latter situtation, a different paradigm must explain the activity of MTAs, and we have proposed that interfering with microtubule (MT) trafficking in interphase cells is the principal mechanism of MTA action (3–5). In breast, ovarian, lung, and head and neck cancers, as well as in most lymphomas, combination regimens that include a MTA and a DNA-damaging agent (DDA) are preferred (Table S1). Although the frequency with which these combinations are used might be fortuitous, it is likely there is a mechanistic basis for this outcome. We hypothesized that by hampering the trafficking of essential DNA repair proteins, MTAs synergize with DDAs, augmenting their toxicity. To explore this theory further we studied the effects of combining a MTA and a DDA in a number of cell models and examined the distribution and biology of nine different proteins involved in DNA repair. We have confirmed the hypothesis and report our findings. 相似文献
105.
Elena López-Knowles Paul M Wilkerson Ricardo Ribas Helen Anderson Alan Mackay Zara Ghazoui Aradhana Rani Peter Osin Ash Nerurkar Lorna Renshaw Alexey Larionov William R Miller J Michael Dixon Jorge S Reis-Filho Anita K Dunbier Lesley-Ann Martin Mitch Dowsett 《Breast cancer research : BCR》2015,17(1)
Introduction
Aromatase inhibitors (AIs) are a vital component of estrogen receptor positive (ER+) breast cancer treatment. De novo and acquired resistance, however, is common. The aims of this study were to relate patterns of copy number aberrations to molecular and proliferative response to AIs, to study differences in the patterns of copy number aberrations between breast cancer samples pre- and post-AI neoadjuvant therapy, and to identify putative biomarkers for resistance to neoadjuvant AI therapy using an integrative analysis approach.Methods
Samples from 84 patients derived from two neoadjuvant AI therapy trials were subjected to copy number profiling by microarray-based comparative genomic hybridisation (aCGH, n = 84), gene expression profiling (n = 47), matched pre- and post-AI aCGH (n = 19 pairs) and Ki67-based AI-response analysis (n = 39).Results
Integrative analysis of these datasets identified a set of nine genes that, when amplified, were associated with a poor response to AIs, and were significantly overexpressed when amplified, including CHKA, LRP5 and SAPS3. Functional validation in vitro, using cell lines with and without amplification of these genes (SUM44, MDA-MB134-VI, T47D and MCF7) and a model of acquired AI-resistance (MCF7-LTED) identified CHKA as a gene that when amplified modulates estrogen receptor (ER)-driven proliferation, ER/estrogen response element (ERE) transactivation, expression of ER-regulated genes and phosphorylation of V-AKT murine thymoma viral oncogene homolog 1 (AKT1).Conclusions
These data provide a rationale for investigation of the role of CHKA in further models of de novo and acquired resistance to AIs, and provide proof of concept that integrative genomic analyses can identify biologically relevant modulators of AI response.Electronic supplementary material
The online version of this article (doi:10.1186/s13058-015-0532-0) contains supplementary material, which is available to authorized users. 相似文献106.
Amber R. Smith Rebecca T. Marquez Wei-Chung Tsao Surajit Pathak Alexandria Roy Jie Ping Bailey Wilkerson Lan Lan Wenjian Meng Kristi L. Neufeld Xiao-Feng Sun Liang Xu 《Oncotarget》2015,6(14):12558-12573
Stem cell marker, Musashi-1 (MSI1) is over-expressed in many cancer types; however the molecular mechanisms involved in MSI1 over-expression are not well understood. We investigated the microRNA (miRNA) regulation of MSI1 and the implications this regulation plays in colorectal cancer. MicroRNA miR-137 was identified as a MSI1-targeting microRNA by immunoblotting and luciferase reporter assays. MSI1 protein was found to be highly expressed in 79% of primary rectal tumors (n=146), while miR-137 expression was decreased in 84% of the rectal tumor tissues (n=68) compared to paired normal mucosal samples. In addition to reduced MSI1 protein, exogenous expression of miR-137 inhibited cell growth, colony formation, and tumorsphere growth of colon cancer cells. Finally, in vivo studies demonstrated that induction of miR-137 can decrease growth of human colon cancer xenografts. Our results demonstrate that miR-137 acts as a tumor-suppressive miRNA in colorectal cancers and negatively regulates oncogenic MSI1. 相似文献
107.
Cytogenetic studies of 68 patients who developed secondary leukemia (SL)/dysmyelopoietic syndrome (DMS) after extensive chemotherapy and/or radiation therapy as well as patients who developed SL/DMS without such treatment showed that those patients who received radiation alone or with chemotherapy had more extensive numerical and structural abnormalities than those who received only chemotherapy. In terms of the specific chromosomal abnormalities, there are no differences between the various treatment groups. Hypodiploidy is the most common form of aneuploidy in these patients, with the most common numerical abnormality being the loss of chromosome 7. The most common structural abnormalities involved chromosomes 3 and 5. When compared with patients with de novo leukemia and DMS, the chromosomal abnormalities in these patients are more complex and extensive. Serial studies revealed that cytogenetic abnormalities do not precede the development of hematologic changes by significant time periods. 相似文献
108.
Weinberg JB; Misukonis MA; Shami PJ; Mason SN; Sauls DL; Dittman WA; Wood ER; Smith GK; McDonald B; Bachus KE 《Blood》1995,86(3):1184-1195
109.
1G10, a monoclonal IgM antibody that identifies a differentiation antigen on human granulocytes and a subpopulation of monocytes, was found to react specifically with glycosphingolipids bearing the Gal beta 1-4(Fuc alpha 1-3)GlcNAc hapten (X determinant). This carbohydrate determinant was found on both glycolipid and glycoprotein molecules isolated from HL-60 cells (a promyelocytic leukemia cell line). Thus, this highly conserved carbohydrate-defined determinant previously described on mouse embryonic and mouse and human carcinoma cells is also expressed as a tissue-specific differentiation antigen on normal human granulocytes. 相似文献
110.